Polio Vaccine SV40 Contamination (1955–63)

Introduction

Simian Virus 40 (SV40) is a polyomavirus that naturally infects rhesus macaque monkeys without typically causing disease in its natural host. Its entry into the human story is a consequence of the mid-twentieth century race to develop polio vaccines. Both Jonas Salk's inactivated polio vaccine (IPV), licensed in 1955, and the early formulations of Albert Sabin's oral polio vaccine (OPV) were produced using rhesus monkey kidney cells as the culture medium. Those cells, as it turned out, were commonly infected with SV40.

The contamination was not discovered until 1960, when NIH virologist Bernice Eddy identified that rhesus monkey kidney cell extracts could induce tumours in hamsters. Eddy's initial findings were not acted upon with the urgency many scientists would later argue was warranted.

Scale of Exposure

Estimates of the number of people who received SV40-contaminated polio vaccines vary by source and methodology. The most commonly cited figures are 10–30 million Americans exposed between 1955 and 1963. Global estimates, accounting for the use of Sabin OPV in mass vaccination campaigns across the Soviet Union, Eastern Europe, and developing countries, suggest the figure may approach 100 million worldwide.

The vaccines were not immediately recalled following the SV40 discovery. Stockpiles of already-manufactured vaccine were allowed to continue in use while new production protocols — using SV40-free African green monkey cells — were phased in. The transition was completed by approximately 1963 in the United States, after which newly manufactured vaccines were SV40-free. Whether and for how long contaminated stocks remained in distribution internationally varies by country and by the specific vaccine manufacturer.

The Bernice Eddy Controversy

Bernice Eddy's 1960 discovery of the tumour-inducing capacity of rhesus monkey kidney cell extracts represented the first indication of the contamination problem. Eddy, who had also earlier raised alarms about inadequate inactivation in early Salk vaccine batches (a concern that proved well-founded during the 1955 Cutter incident), was reportedly discouraged from publicising her SV40 findings and was temporarily reassigned from polio work.

Whether Eddy's treatment represented a deliberate suppression of safety concerns for commercial or reputational reasons, or reflected the ordinary institutional friction surrounding inconvenient findings in a large government agency, is disputed in the historical record. Eddy herself later gave congressional testimony about the vaccine safety culture at NIH in the period.

In 2013, the CDC removed a webpage that had contained information about the SV40 contamination and its potential links to cancer. The removal was cited by critics as evidence of ongoing institutional suppression; the CDC characterised the removal as routine content maintenance.

SV40 and Cancer: The Scientific Debate

The cancer-causation question is the most contested aspect of this issue. The sequence of findings:

Animal evidence (strong): SV40 reliably induces sarcomas, brain tumours, and mesotheliomas in hamsters. The biological mechanism is established: SV40's large T-antigen binds and inactivates the tumour suppressors p53 and Rb, disrupting normal cell cycle regulation.

Human tumour detection (contested): Researchers Michele Carbone and Harvey Pass reported in 1994 that SV40 DNA sequences could be detected in a significant proportion of human mesothelioma samples. Subsequent studies by other researchers reported similar findings in mesothelioma, brain tumours (particularly ependymomas and choroid plexus tumours), and some osteosarcomas. These findings were published in peer-reviewed journals and generated substantial scientific interest.

Epidemiologic studies (inconclusive): When researchers attempted to determine whether people who received contaminated vaccines in 1955–63 had elevated cancer rates compared to those vaccinated after 1963 or not vaccinated, the results were mixed. The landmark NCI study by Eric Engels (2004) examined cancer incidence in a cohort and found no statistically significant elevated risk for the tumour types associated with SV40. Critics of the Engels study argued methodological limitations — exposure misclassification, latency periods, lack of individual-level vaccination records — undermined its conclusions.

IOM 2002 review: The Institute of Medicine's Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer (2002) concluded that the biological mechanism was plausible and that the evidence was "inadequate to accept or reject" a causal relationship with cancer. This finding — epidemiologically inconclusive but biologically plausible — is the current scientific consensus position.

What Is Established and What Is Not

Established facts: SV40 contaminated polio vaccines produced from rhesus monkey kidney cells. Tens of millions of people were exposed before contamination-free production was achieved. SV40 is a potent oncovirus in laboratory animals. SV40 DNA has been detected in human tumour samples. The FDA and NIH were aware of the contamination issue from 1960.

Not established: Whether SV40 causes cancer in humans at population-significant rates. Whether the detected SV40 DNA in human tumours represents active infection causing those tumours or is a laboratory artefact or incidental finding. Whether the people who received contaminated vaccines have elevated cancer rates above background.

Verdict

Partially true. The contamination is documented and is not disputed by the scientific or public health community. The harm — particularly long-term cancer risk — remains scientifically unresolved. The framing that contamination was "covered up" has partial support in Eddy's treatment and the 2013 CDC page removal, but characterising the regulatory response as suppression versus ordinary institutional dysfunction requires more evidence than is available. The cancer-causation question is genuinely open, not definitively resolved in either direction.

What Would Change Our Verdict

• Large-scale cohort studies with individual-level vaccination records comparing cancer incidence between people vaccinated with confirmed contaminated batches and those vaccinated post-1963
• Definitive molecular evidence establishing whether SV40 detected in human tumours is causally integrated into the tumour genome or an artefact
• Declassified regulatory documents showing deliberate suppression of Eddy's findings for commercial or political reasons

Geographic Variation in Osteosarcoma Findings

A 2009 PCR-based study by Heinsohn and colleagues examined 277 osteosarcoma tumour samples from Hungary and Germany alongside blood samples from healthy volunteers in both countries. SV40 sequences were detected in 52% of the combined osteosarcoma samples overall, with striking geographic disparity: 74% of Hungarian tumour samples carried high viral copy numbers, compared with only 22% of German samples carrying much lower copy numbers. Healthy blood donors showed only weak SV40 positivity, again somewhat higher in Hungary than Germany. Proponents of a causal link point to this tumour-versus-control differential as corroborating evidence. Sceptics note that the geographic inconsistency — a roughly threefold difference in detection rate between two neighbouring countries — is difficult to reconcile with a single, uniform viral cause of osteosarcoma, and that comparing tumour tissue to blood, rather than matched non-tumour tissue from the same patients, leaves open whether SV40 is a bystander "passenger" sequence rather than a causal "driver."

Large Cohort Studies: Denmark and the United States

The largest population-level tests of the cancer hypothesis come from national cohort studies. A 2003 analysis by Eric Engels and colleagues, published in the Journal of the National Cancer Institute, tracked cancer incidence across roughly 69.5 million person-years of follow-up in Denmark, where most children born in the mid-to-late 1950s received SV40-contaminated poliovirus vaccine. It found no increased cancer incidence among the exposed cohort — including no excess of mesothelioma, ependymoma, choroid plexus tumours, or non-Hodgkin lymphoma, the cancers most often linked to SV40 in laboratory and tumour-detection studies. Two further 2004 NCI studies agreed from different angles: one found the pattern of cancers among nearly 55,000 U.S. children whose mothers received polio vaccine during pregnancy did not match what SV40 causation would predict; another followed military veterans given an SV40-contaminated Army adenovirus vaccine in 1959–61 and likewise found no elevated cancer risk.

Congressional Scrutiny and Modern Vaccine Testing

The episode was significant enough to prompt direct congressional review. On November 13, 2003, the House Government Reform Committee's Subcommittee on Human Rights and Wellness held a hearing titled "Preventing Another SV40 Tragedy: Are Today's Vaccine Safety Protocols Effective?", examining whether modern oversight could prevent a repeat. Practice has since changed: polio vaccine seed stocks and production cell lines are now required, under WHO recommendations and European Pharmacopoeia standards, to be screened by PCR and antibody assays specifically for SV40 before release — a requirement adopted in direct response to the 1955–63 episode. No SV40 contamination of a licensed, currently distributed polio vaccine has been documented since.

A Second Discoverer: Maurice Hilleman

Bernice Eddy was not alone in identifying the vacuolating agent. Merck virologist Maurice Hilleman, working with colleague Ben Sweet, independently characterised the same virus in monkey kidney cell cultures and vaccine stocks in 1960, publishing it as SV40. Hilleman — who went on to develop more vaccines than any other scientist in history — was among the first researchers to warn publicly that primate cell cultures could harbour undetected viral passengers, a concern that helped drive the industry-wide shift to screened, characterised cell substrates.